Advertisement
Screener

CAREDX, INC. (CDNA) Overview

CAREDX, INC. (CDNA) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 2.07; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 0.05; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.03; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.16; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$14.26$20.25$28.77$40.87$58.05$82.462025-11-062026-11-06$4.66$8.27$14.70$26.12$46.40$82.462021-11-082026-11-06$0.75$2.00$5.32$14.16$37.70$100.382016-11-072026-11-06$0.75$2.00$5.32$14.16$37.70$100.382014-07-172026-11-06$0.75$2.00$5.32$14.16$37.70$100.382014-07-172026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$78.53
Previous close
$64.02
Change
$14.51
Change (%)
22.66%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

CDNA
+239.81%
S&P 500
(m)

1 year

CDNA
+330.82%
S&P 500
(m)

3 years

CDNA
+814.57%
S&P 500
(m)

5 years

CDNA
+5.77%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 2.07

-0.270.360.991.622.2531 Mar 2025: estimate (m); actual -0.1931 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.1630 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.0330 Sept 2025(m)31 Mar 2026: estimate (m); actual 0.0531 Mar 2026(m)30 Jun 2026: estimate (m); actual 2.0730 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)2.07(m)(m)
1 Jan 202631 Mar 2026(m)0.05(m)(m)
1 Jul 202530 Sept 2025(m)0.03(m)(m)
1 Apr 202530 Jun 2025(m)-0.16(m)(m)
1 Jan 202531 Mar 2025(m)-0.19(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.40

-3.62-2.44-1.25-0.071.1131 Dec 2021: estimate (m); actual -0.5931 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.4431 Dec 2022(m)31 Dec 2023: estimate (m); actual -3.5431 Dec 2023(m)31 Dec 2024: estimate (m); actual 0.9331 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.4031 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.40(m)(m)
1 Jan 202431 Dec 2024(m)0.93(m)(m)
1 Jan 202331 Dec 2023(m)-3.54(m)(m)
1 Jan 202231 Dec 2022(m)-1.44(m)(m)
1 Jan 202131 Dec 2021(m)-0.59(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 131.95M ■ Earnings 110.64M — Profit margin 83.85%

-20.43M-4.8%35.80M25.1%92.04M55.0%148.27M84.8%30 Sept 2025: revenue 100.06M; earnings 1.68M; profit margin 1.67%30 Sept 202531 Dec 2025: revenue 108.39M*; earnings -4.11M*; profit margin -3.79%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 117.70M; earnings 2.81M; profit margin 2.39%31 Mar 202630 Jun 2026: revenue 131.95M; earnings 110.64M; profit margin 83.85%30 Jun 2026

31 Dec 2025 ■ Revenue 379.81M ■ Earnings -21.35M — Profit margin -5.62%

-258.69M-68.9%-23.06M-40.3%212.58M-11.8%448.22M16.7%31 Dec 2022: revenue 321.79M; earnings -76.61M; profit margin -23.81%31 Dec 202231 Dec 2023: revenue 280.32M; earnings -190.28M; profit margin -67.88%31 Dec 202331 Dec 2024: revenue 333.79M; earnings 52.55M; profit margin 15.74%31 Dec 202431 Dec 2025: revenue 379.81M; earnings -21.35M; profit margin -5.62%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$78.53(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$78.53High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning CDNA

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
645.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.23M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
13.33%*
Total return · month
28.58%*
Total return · quarter
118.65%*
Total return · half year
281.53%*
Total return · year to date
239.81%*
Total return · 1 year
330.82%*
Total return · 3 years
814.57%*
Total return · 5 years
5.77%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

CAREDX, INC. Overview

View more →

(m)

(m)

SEC CIK
1217234
Industry (SIC)
8071 Services-Medical Laboratories
Country of operation
United States
Business address
8000 MARINA BLVD, 4TH FLOOR, BRISBANE, California, 94005, United States
Fiscal year end
1231
Phone
415-287-2300

Similar stocks

Stock NameCountryMarket CapPE Ratio
Celcuity Inc. (CELC)United States$3.887B-22.62
VERACYTE, INC. (VCYT)United States$3.904B41.21
Fortrea Holdings Inc. (FTRE)United States$1.903B-19.43
Personalis, Inc. (PSNL)United States$1.769B-13.30
CASTLE BIOSCIENCES INC (CSTL)United States$1.074B-37.45
Lumexa Imaging Holdings, Inc. (LMRI)United States$0.951B
GRAIL, Inc. (GRAL)United States$5.591B-7.78
RadNet, Inc. (RDNT)United States$5.611B-229.65
Fulgent Genetics, Inc. (FLGT)United States$0.593B-6.70
BIODESIX INC (BDSX)United States$0.312B